Nymox secures Italian deal for Alzheimer's test:
This article was originally published in Clinica
Nymox Pharmaceutical, of Maywood, New Jersey, has entered into a distribution agreement with Padua-based Italian medical diagnostics company Alifax, to market and sell Nymox's AlzheimAlert product in Italy. Nymox's urine test, an aid in the diagnosis of Alzheimer's disease, is available through the company's CLIA-certified clinical reference laboratory in the US, although a PMA application was rejected by the FDA last year and a second application has been lodged (see Clinica 1136, p 18). A recent report by the World Health Organization for the European Union has identified Alzheimer's disease as a major healthcare priority for Europe. Worldwide estimates of the current number of people with the condition range from 15 to 20 million.